Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2025 07:20 ET | Source: InflaRx N.V.

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

JENA, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
September 12, 2025 08:30 ET | Source: InflaRx N.V.

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the...
August 21, 2025 07:30 ET | Source: InflaRx N.V.

InflaRx Announces Participation in September Investor Conferences

JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
August 07, 2025 07:30 ET | Source: InflaRx N.V.

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson...
July 31, 2025 07:30 ET | Source: InflaRx N.V.

InflaRx to Report Second Quarter 2025 Results on August 7, 2025

JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
July 11, 2025 16:15 ET | Source: InflaRx N.V.

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

JENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...
May 28, 2025 01:30 ET | Source: InflaRx N.V.

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced...
May 22, 2025 07:30 ET | Source: InflaRx N.V.

InflaRx to Participate in Upcoming Investor Conferences

JENA, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
May 07, 2025 07:30 ET | Source: InflaRx N.V.

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trialsMultiple near-term catalysts anticipated with the...
April 30, 2025 07:30 ET | Source: InflaRx N.V.

InflaRx to Report First Quarter 2025 Results on May 7, 2025

JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...